文献速递炎症性肠病

同种异体扩增脂肪干细胞(Cx601)治疗克罗恩病复杂肛瘘的长期疗效与安全性

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.
PubMed 文献 · Gastroenterology · 2017-12-24

一项在欧洲和以色列49家医院开展的双盲3期随机对照试验,纳入212例克罗恩病合并难治性引流性复杂肛瘘患者,按1:1随机接受单次局部注射1.2亿Cx601细胞或安慰剂联合标准治疗。第52周时,Cx601组联合缓解率56.3% vs 对照组38.6%(差值17.7个百分点,95%CI 4.2-31.2,P=0.010),临床缓解率59.2% vs 41.6%(差值17.6个百分点,95%CI 4.1-31.1,P=0.013);安全性维持至第52周,不良事件发生率分别为76.7%和72.5%。

要点

  • 第52周Cx601组联合缓解率56.3%,对照组38.6%,差值17.7个百分点(95%CI 4.2-31.2,P=0.010)。
  • 第52周Cx601组临床缓解率59.2%,对照组41.6%,差值17.6个百分点(95%CI 4.1-31.1,P=0.013)。
  • 不良事件发生率Cx601组76.7%,对照组72.5%,安全性维持至第52周。

核心结论

  • 在克罗恩病合并难治性复杂肛瘘的3期试验中,与安慰剂相比,Cx601在1年后封闭外口方面安全且有效。

研究设计与样本

  • 在欧洲和以色列49家医院开展的双盲研究,纳入212例克罗恩病合并难治性引流性复杂肛瘘患者。
  • 患者按1:1随机分配至单次局部注射1.2亿Cx601细胞组或安慰剂(对照)组,均联合标准治疗。
  • 疗效终点在改良意向治疗人群(随机分配、接受治疗且有至少1次基线后疗效评估)中于第52周评估。

主要发现

  • 第52周联合缓解率Cx601组56.3% vs 对照组38.6%,差值17.7个百分点(95%CI 4.2-31.2,P=0.010)。
  • 第52周临床缓解率Cx601组59.2% vs 对照组41.6%,差值17.6个百分点(95%CI 4.1-31.1,P=0.013)。
  • 安全性维持至第52周,不良事件发生率Cx601组76.7% vs 对照组72.5%。
  • 研究主要终点第24周结果此前已报告:联合缓解率Cx601组51.5% vs 对照组35.6%,差值15.8个百分点(97.5%CI 0.5-31.2,P=0.021)。

关键数值与推荐

  • 联合缓解定义为基线时引流的全部治疗外口闭合且无大于2 cm的集合,经磁共振成像确认。
  • 临床缓解定义为无引流瘘管。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Therapies for perianal fistulas in patients with Crohn's disease are often ineffective in producing long-term healing. We performed a randomized placebo-controlled trial to determine the long-term efficacy and safety of a single local administration of allogeneic expanded adipose-derived stem cells (Cx601) in patients with Crohn's disease and perianal fistulas. METHODS: We performed a double-blind study at 49 hospitals in Europe and Israel, comprising 212 patients with Crohn's disease and treatment-refractory, draining, complex perianal fistulas. Patients were randomly assigned (1:1) to groups given a single local injection of 120 million Cx601 cells or placebo (control), in addition to the standard of care. Efficacy endpoints evaluated in the modified intention-to-treat population (randomly assigned, treated, and with 1 or more post-baseline efficacy assessment) at week 52 included combined remission (closure of all treated external openings draining at baseline with absence of collections >2 cm, confirmed by magnetic resonance imaging) and clinical remission (absence of draining fistulas). RESULTS: The study's primary endpoint, at week 24, was previously reported (combined remission in 51.5% of patients given Cx601 vs 35.6% of controls, for a difference of 15.8 percentage points; 97.5% confidence interval [CI] 0.5-31.2; P = .021). At week 52, a significantly greater proportion of patients given Cx601 achieved combined remission (56.3%) vs controls (38.6%) (a difference of 17.7 percentage points; 95% CI 4.2-31.2; P = .010), and clinical remission (59.2% vs 41.6% of controls, for a difference of 17.6 percentage points; 95% CI 4.1-31.1; P = .013). Safety was maintained throughout week 52; adverse events occurred in 76.7% of patients in the Cx601 group and 72.5% of patients in the control group. CONCLUSION: In a phase 3 trial of patients with Crohn's disease and treatment-refractory complex perianal fistulas, we found Cx601 to be safe and effective in closing external openings, compared with placebo, after 1 year. ClinicalTrials.gov no: NCT01541579.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Panés J, García-Olmo D, Van Assche G, et al. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2017. PMID: 29277560. doi:10.1053/j.gastro.2017.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。